ENTRY       D11126                      Drug
NAME        Navicixizumab (USAN/INN)
FORMULA     C6481H9981N1719O2030S54
EXACT_MASS  146098.5544
MOL_WEIGHT  146189.4051
SEQUENCE    (Heavy chain)
            QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYWMHWVRQA PGQGLEWMGD INPSNGRTSY
            KEKFKRRVTL SVDKSSSTAY MELSSLRSED TAVYFCTIHY DDKYYPLMDY WGQGTLVTVS
            SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
            SGLYSLSSVV TVPSSNFGTQ TYTCNVDHKP SNTKVDKTVE RKCCVECPPC PAPPVAGPSV
            FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVQFNWYVD GVEVHNAKTK PREEQFNSTF
            RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA PIEKTISKTK GQPREPQVYT LPPSREKMTK
            NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPMLKS DGSFFLYSKL TVDKSRWQQG
            NVFSCSVMHE ALHNHYTQKS LSLSPGK
            (heavy chain)
            QVQLVQSGAE VKKPGASVKI SCKASGYSFT AYYIHWVKQA PGQGLEWIGY ISNYNRATNY
            NQKFKGRVTF TTDTSTSTAY MELRSLRSDD TAVYYCARDY DYDVGMDYWG QGTLVTVSSA
            STKGPSVFPL APCSRSTSES TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSNFGTQTY TCNVDHKPSN TKVDKTVERK CCVECPPCPA PPVAGPSVFL
            FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV
            VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLP PSREEMTKNQ
            VSLTCLVEGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG SFFLYSELTV DKSRWQQGNV
            FSCSVMHEAL HNHYTQKSLS LSPGK
            (Light chain)
            DIVMTQSPDS LAVSLGERAT ISCRASESVD NYGISFMKWF QQKPGQPPKL LIYAASNQGS
            GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQSKEVPW TFGGGTKVEI KRTVAAPSVF
            IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
            STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
            (Disulfide bridge: H22-H96, H135-L218, H148-H204, H223-h221, H224-h222, H227-h225, H230-h228, H261-H321, H367-H425, h22-h96, h133-L'218, h146-h202, h259-h319, h365-h423, L23-L92, L138-L198, L'23-L'92, L'138-L'198)
  TYPE      Peptide
EFFICACY    Antineoplastic
  TYPE      Monoclonal antibody, bispecific antibody
COMMENT     Treatment of cancer
TARGET      DLL4 [HSA:54567] [KO:K06051]
            VEGFA [HSA:7422] [KO:K05448]
  PATHWAY   hsa04014(7422)  Ras signaling pathway
            hsa04151(7422)  PI3K-Akt signaling pathway
            hsa04330(54567)  Notch signaling pathway
            hsa04370(7422)  VEGF signaling pathway
            hsa05200(54567+7422)  Pathways in cancer
BRITE       Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Growth factors (RTK-binding)
                VEGFA
                 D11126  Navicixizumab (USAN/INN)
             Not elsewhere classified
              Signaling molecules
               Notch signaling
                DLL4
                 D11126  Navicixizumab (USAN/INN)
DBLINKS     CAS: 1638338-43-8
            PubChem: 376219050
///
